Last €23.81 EUR
Change Today 0.00 / 0.00%
Volume 0.0
EUZ On Other Exchanges
Symbol
Exchange
OTC US
Xetra
As of 1:15 PM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

eckert & ziegler strahlen un (EUZ) Snapshot

Open
€24.11
Previous Close
€24.00
Day High
€24.28
Day Low
€23.81
52 Week High
01/20/14 - €30.67
52 Week Low
03/14/14 - €22.55
Market Cap
126.0M
Average Volume 10 Days
3.4K
EPS TTM
€1.79
Shares Outstanding
5.3M
EX-Date
05/23/14
P/E TM
13.3x
Dividend
€0.60
Dividend Yield
2.51%
Current Stock Chart for ECKERT & ZIEGLER STRAHLEN UN (EUZ)

Related News

No related news articles were found.

eckert & ziegler strahlen un (EUZ) Related Businessweek News

No Related Businessweek News Found

eckert & ziegler strahlen un (EUZ) Details

Eckert & Ziegler Strahlen & Medizintechnik AG and its subsidiaries provide isotope technology for medical, scientific, and industrial use primarily in Europe. The company’s Radiation Therapy segment produces and distributes medical devices for brachytherapy, a form of radiotherapy that treats cancer by irradiation from a short distance. This segment offers seeds for the treatment of localised prostate cancer; high dose rate (HDR) afterloaders to treat gynaecological cancers and other tumour sites; applicators for intraluminal, interstitial, intracavitary, and intraoperative treatments, as well as surface mould treatments; and support software of HDR planning. The Radiation Therapy segment also provides products for temporary brachytherapy of eye cancers and radiotherapy accessories. This segment’s products and equipment are intended for use by oncologists, radio-therapists, urologists, ophthalmologists, and medical physicists. Its Isotope Products segment provides sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration, and environmental monitoring sources and solutions; and bulk radioisotopes for pharmaceutical, therapeutic, and industrial product manufacturers. This segment offers custom and one-off design and manufacturing services. The company’s Radiopharma segment operates in the field of molecular imaging and nuclear medicine supplying various radiopharmaceuticals, radiochemicals, and related equipment for the synthesis and radiochromatography of PET/SPECT tracers and other radioisotopes. This segment offers products in the categories of radiosynthesis technology, radiochromatography, and radionuclides. Its Environmental Services segment collects, measures, sorts, treats, and packs low level radioactive waste from hospitals, research institutes, and industry for its final disposal. Eckert & Ziegler Strahlen & Medizintechnik AG was founded in 1992 and is headquartered in Berlin, Germany.

679 Employees
Last Reported Date: 05/6/14
Founded in 1992

eckert & ziegler strahlen un (EUZ) Top Compensated Officers

Chairman of The Executive Board, Chief Execut...
Total Annual Compensation: €512.0K
Head of Radiopharma Segment, Member of The Ex...
Total Annual Compensation: €292.0K
Head of Radiation Therapy Segment, Member of ...
Total Annual Compensation: €282.0K
Compensation as of Fiscal Year 2013.

eckert & ziegler strahlen un (EUZ) Key Developments

Eckert & Ziegler Strahlen & Medizintechnik AG Reports Earnings Results for the First Quarter Ended March 2014; Provides Earnings Guidance for the Year 2014

Eckert & Ziegler Strahlen & Medizintechnik AG reported earnings results for the first quarter ended March 2014. For the quarter, the company increased sales by 16% year on year in the first quarter of 2014 to EUR 30.7 million. EBIT soared by 25% to EUR 3.0 million due to additional contribution margins from the increase in sales as well as the absence of overall negative special effects in the prior-year quarter. As the losses reported by the Radiation Therapy segment are shared with minority shareholders, they had less of an impact on the group's net profit for the quarter, which grew faster than EBIT by 32% to EUR 1.6 million. The company’s board has confirmed the sales and earnings growth of at least 10% forecast for 2014 in the annual financial statements for 2013. In concrete terms, sales are expected to grow to EUR 134 million and net profit to EUR 10.5 million or EUR 2.00 per share.

Eckert & Ziegler Strahlen & Medizintechnik AG, Q1 2014 Earnings Call, May 06, 2014

Eckert & Ziegler Strahlen & Medizintechnik AG, Q1 2014 Earnings Call, May 06, 2014

Eckert & Ziegler Strahlen & Medizintechnik AG Reports Earnings Results for the Full Year 2013; Provides Financial Guidance for Fiscal Year 2014

Eckert & Ziegler Strahlen & Medizintechnik AG reported earnings results for the full year 2013. For the period, the company showed a slight decrease in sales from EUR 120 to EUR 117 million. The decisive factors for this development were the decline in sales in industrial components, implants and instruments, the planned exit from the accessories trade in France as well as the unfavorable EUR/USD exchange rate. Additional sales from acquisitions were unable to compensate for these effects. Consolidated net profit after taxes and minority interests fell by 12% from EUR 10.3 million to EUR 9.1 million, and earnings per share dropped EUR 0.23 per share to EUR 1.72. The main reason for this was the decline in the gross margin, which was down 12% due to one-off effects although sales only registered a 2% decline. Higher sales costs as a result of higher one time waste costs as well as a shift in the product mix to low-margin products were also responsible. Overall, sales and earnings are expected to see at least 10% growth in fiscal year 2014. This corresponds to sales of some EUR 129 million and net profit of around EUR 10 million (EPS approx. EUR 1.90 per share) for the year. Internal planning figures are considerably higher than these threshold values.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EUZ:GR €23.81 EUR 0.00

EUZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
General Electric Co $25.91 USD -0.11
Nordion Inc C$13.89 CAD 0.00
View Industry Companies
 

Industry Analysis

EUZ

Industry Average

Valuation EUZ Industry Range
Price/Earnings 13.3x
Price/Sales 1.0x
Price/Book 1.5x
Price/Cash Flow 13.3x
TEV/Sales 0.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ECKERT & ZIEGLER STRAHLEN UN, please visit www.ezag.de. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.